What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?

Abstract

The costs of treating and managing prostate cancer are high and these result in a substantial financial burden for the Australian MBS. Costs attributable to prostate cancer appear to vary widely based on initial treatment and these are likely to increase with the introduction of more expensive services and pharmaceuticals. There is a pressing need for better prognostic tools to distinguish between indolent and aggressive prostate tumors to reduce potential over treatment and help ease the burden of prostate cancer.

'…If I don't have that sort of money again, what happens?': adapting a qualitative model to conceptualise the consequences of out-of-pocket expenses for cancer patients in mixed health systems

“…2 The worst effects of financial stress are termed 'financial toxicity', 3,4 which is measured through monetary (absolute costs accrued by the patient), objective (methods used to ease financial burden) and subjective (perceived financial burden) measures. 2 Although some researchers and clinicians are attempting to incorporate price transparency into conversations with patients, 5,6 the effects of cancer costs remain an issue of growing importance, [7][8][9][10] and are a primary issue that Australian health consumers and cancer patient organisations have identified requiring further action. [11][12][13] To support health services and policy makers to address their concerns, a model or framework underpinning the patient experiences in a public-private setting would contribute towards identifying areas to target and address.…”

Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017

“…Prostate cancer is one of the highest increasing cancers in terms of medical costs with a tremendous economic burden (Norlund et al, 2003;Fourcade et al, 2010;Felix et al, 2011;Mariotto et al, 2011;Luengo-Fernandez et al, 2013;Mervin et al, 2017;Restelli et al, 2017;Satoh et al, 2018;Zhuo et al, 2019). Previous studies have shown that metastatic progression contributed to an increase in costs and medical resource use for prostate cancer patients (Penson et al, 2004;Li et al, 2017;Satoh et al, 2018).…”

“…Being older at diagnosis and higher comorbidity would affect treatment choice of prostate cancer patients and be associated with increased costs (Wilson et al, 2007;Krahn et al, 2010). Studies on the economic burden or costs of prostate cancer were mainly focused on the United States, Europe countries (Sanyal et al, 2013;Smith-Palmer et al, 2019), or other developed countries (Grover et al, 1999;Grover et al, 2000;Krahn et al, 2010;Kitazawa et al, 2015;Mervin et al, 2017;Satoh et al, 2018). Only a few studies described the medical expenditure of Chinese patients with metastatic prostate cancer and presented a high prevalence of bone metastasis among Chinese prostate cancer patients (Qian et al, 2019;Zhuo et al, 2019).…”